Analysis of tumors treated with AG14361 and lestaurtinib as mono-treatment and combination therapy. Images (A) and quantification (B) of TUNEL assay for xenograft tumors from 92 J-shBRCA1 and 92 J-wtBRCA1 cell lines. (C, D) Images (C) and quantification (D) of PCNA immunochemical staining for the same tumors used in (A, B). Data show the mean of three different readings and are marked by columns with ± standard deviation (SD) error bars. PCNA, proliferating cell nuclear antigen; shBRCA1, sample with short hairpin RNA (shRNA) against breast cancer type 1 susceptibility (BRCA1); TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling; wtBRCA1, sample with wild-type BRCA1 status.